Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Panalgo’s IHD Platform to Be Used by the European Medicines Agency for Real-World Data Analytics

Panalgo’s IHD software to be used by the EMA to rapidly answer questions around drug safety and efficacy and better understand real-world medication use

Panalgo, a leading healthcare analytics company, announced that its Instant Health Data (IHD) platform will be used by the European Medicines Agency (EMA) to facilitate the analysis of real-world data.

EMA will use IHD to undertake rapid analyses of Electronic Healthcare Data (EHDs) accessible in-house (currently data from the UK, France, and Germany) to more quickly examine drug utilization, assess safety/efficacy, understand how treatments perform in real-world settings, and support public health efforts in the European Union (EU).

Recommended AI News: Insight Awarded Global SASE Partner of the Year from Palo Alto Networks

Related Posts
1 of 14,263

EMA’s scientific committees will benefit from more rapid support for informed decision-making at the population level, including the benefit-risk of medicines, product life cycle analyses, and other clinical insights to better support public health goals.

To make the choice of analytics software, EMA conducted a rigorous evaluation of IHD as well as several other platforms, which included proof of concept testing, in-depth hands-on analyses and verification of results. IHD received the highest score in the evaluation.

Recommended AI News: Booz Allen Leads New Frost & Sullivan Security Report

“We are excited to partner with the EMA to support its mission of ensuring the efficacy and safety of medical products throughout the EU. Our company is strongly aligned with the EMA’s public health goals, for which timely evidence-based insights are of particular importance, especially during this COVID-19 pandemic,” said Joseph Menzin, PhD, Chief Executive Officer of Panalgo. “Most of Panalgo’s life sciences clients already rely on IHD to perform rapid analyses that support regulatory initiatives. The IHD platform will be a valuable tool to allow collaboration between drug manufacturers and regulatory agencies, such as the EMA.”

Recommended AI News: Cleo Cements Integration Market Leadership with Top Rankings in iPaaS and EDI

Leave A Reply

Your email address will not be published.